Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976741 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
NCT01976741 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 168 participants.
The verdict
NCT01976741, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
Study Summary
* This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) received the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1163877. The relative bioavailability of liquid service formulation and tablets was determined. * After the MTD was defined patients with solid tumors (all comers), lung cancer (lung adenocarcinoma \& squamous non-small cell lung cancer), head and neck cancer or bladder cancer was enrolled according to their FGFR expression profile (biomarker stratification). * The study also assessed the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of BAY1163877. * BAY1163877 was given twice daily as oral application. Treatment was stopped if the tumor continued to grow, if side effects, which the patient cannot tolerate, occurred or if the patient decided to exit treatment.
Interventions
- DRUG Rogaratinib (BAY1163877) oral solution
- DRUG Rogaratinib (BAY1163877) oral tablet
- DRUG Rogaratinib (BAY1163877) 800 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2013-12-30 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976741
The ClinicalTrials.gov registry entry for NCT01976741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rogaratinib (BAY1163877) oral solution is the first listed.
NCT01976741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01976741 about?
NCT01976741 is a clinical study titled "Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)". * This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) received the study drug treatment in a dose-escalation sc...
What is the current status of trial NCT01976741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2013-12-30. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT01976741?
The interventions under investigation include: Rogaratinib (BAY1163877) oral solution (DRUG), Rogaratinib (BAY1163877) oral tablet (DRUG), Rogaratinib (BAY1163877) 800 mg BID (DRUG).
Who is sponsoring clinical trial NCT01976741?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.